Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure

JACC: Heart Failure

Volumn 1, Issue 2, 2013, Pages 103-111

  Packer, Milton ^a   Colucci, Wilson ^b   Fisher, Lloyd ^c   Massie, Barry M ^d   Teerlink, John R ^d   Young, James ^e   Padley, Robert J ^f   Thakkar, Roopal ^f   Delgado Herrera, Leticia ^f   Salon, Jeffrey ^f   Garratt, Chris ^g   Huang, Bidan ^f   Sarapohja, Toni ^g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f ABBOTT LABORATORIES   (United States)

^g ORION CORPORATION   (Finland)

Author keywords

Heart failure; Inotropic agents; Trials

Indexed keywords

LEVOSIMENDAN; PLACEBO;

ACUTE HEART FAILURE; ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

HEART FAILURE; INOTROPIC AGENTS; TRIALS;

CARDIOTONIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDAZINES;

EID: 84877960102     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2012.12.004     Document Type: Article

References (30)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
2. Fonarow G.C. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 2002, 3(Suppl 4):S18-S27.
3. Yancy C.W., Lopatin M., Stevenson L.W., De Marco T., Fonarow G.C. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006, 47:76-84.
4. Shah M.R., Hasselblad V., Stinnett S.S., et al. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. Eur J Heart Fail 2002, 4:297-304.
5. Cuffe M.S., Califf R.M., Adams K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
6. O'Connor C.M., Gattis W.A., Adams K.F., et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003, 41:1452-1457.
7. O'Connor C.M., Gattis W.A., Teerlink J.R., Adams K.F., Gheorghiade M. Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure. Am Heart J 2003, 145:S47-S50.
8. Teerlink J.R. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol 2005, 96:59G-67G.
9. Teerlink J.R. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J 2003, 145:S26-S33.
10. O'Connor C.M., Stough W.G., Gallup D.S., Hasselblad V., Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005, 11:200-205.
11. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531-1540. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF).
12. Papp Z., Edes I., Fruhwald S., et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012, 159:82-87.
13. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000, 36:1903-1912.
14. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. on behalf of the Study Investigators. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000, 102:2222-2227.
15. Moiseyev V.S., Poder P., Andrejevs N., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002, 23:1422-1432.
16. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360:196-202.
17. Lilleberg J., Laine M., Palkama T., Kivikko M., Pohjanjousi P., Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007, 9:75-82.
18. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001, 7:176-182.
19. de Lissovoy G., Fraeman K., Teerlink J.R., et al. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Health Econ 2010, 11:185-193.
20. Lehtonen L., Sundberg S. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol 2002, 58:449-452.
21. Mebazaa A., Nieminen M.S., Filippatos G.S., et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009, 11:304-311.
22. Kivikko M., Antila S., Eha J., Lehtonen L., Pentikäinen P.J. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002, 40:465-471.
23. Kivikko M., Lehtonen L., Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003, 107:81-86.
24. Capomolla S., Febo O., Opasich C., et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 2001, 3:601-610.
25. Landoni G., Biondi-Zoccai G., Greco M., et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012, 40:634-646.
26. O'Connor C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999, 138:78-86.
27. Abraham W.T., Adams K.F., Fonarow G.C., et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005, 46:57-64.
28. Tacon C.L., McCaffrey J., Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 2012, 38:359-367.
29. Archan S., Toller W. Levosimendan: current status and future prospects. Curr Opin Anaesthesiol 2008, 21:78-84.
30. Lunghetti S., Palmerini E., Urselli R., et al. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure. Cardiol J 2011, 18:532-537.